Share This Page
Drug Sales Trends for SUMAVEL DOSE
✉ Email this page to a colleague
Annual Sales Revenues and Units Sold for SUMAVEL DOSE
| Drug Name | Revenues (USD) | Units | Year |
|---|---|---|---|
| SUMAVEL DOSE | ⤷ Try for Free | ⤷ Try for Free | 2022 |
| SUMAVEL DOSE | ⤷ Try for Free | ⤷ Try for Free | 2021 |
| SUMAVEL DOSE | ⤷ Try for Free | ⤷ Try for Free | 2020 |
| >Drug Name | >Revenues (USD) | >Units | >Year |
Market Analysis and Sales Projections for Sumavel DosePro
Introduction to Sumavel DosePro
Sumavel DosePro is a revolutionary drug delivery system designed for the acute treatment of migraines and cluster headaches. It is a prefilled, single-dose, needle-free subcutaneous delivery system containing sumatriptan succinate, a well-established triptan for migraine relief[1][4][5].
Market Context: Migraine Treatment
The migraine treatment market is substantial and growing. As of 2023, the global migraine drugs market was valued at $4.2 billion and is projected to reach $6.3 billion by 2032, with a Compound Annual Growth Rate (CAGR) of 4.3% during 2024-2032. This growth is driven by advancements in novel therapies and the increasing prevalence of migraines[3].
Unique Selling Points of Sumavel DosePro
Needle-Free Delivery
Sumavel DosePro stands out with its innovative needle-free delivery system, which uses compressed nitrogen gas to penetrate the skin and deliver the medication subcutaneously. This technology makes it easier for patients to self-administer the drug, especially those who are averse to needles[5].
Rapid Onset of Action
The drug can provide onset of migraine pain relief in as little as ten minutes for some patients, making it a preferred option for acute treatment[4].
Convenience and Ease of Use
Sumavel DosePro is designed for simple and convenient administration, which can be particularly beneficial for patients experiencing severe migraine episodes where oral medications may not be effective or practical[4].
Sales Performance and Revenue
Since its launch in January 2010, Sumavel DosePro has shown promising sales figures. In the first year, total U.S. net product revenue from sales of Sumavel DosePro was $18.7 million, with over 35,200 aggregate dispensed prescriptions. By the end of 2013, the reimbursement claims approval rate had increased to approximately 83%[2][4].
Market Penetration and Adoption
Sumavel DosePro is promoted to a wide range of healthcare providers, including neurologists, headache specialists, primary care physicians, OB/GYNs, emergency medicine physicians, and urologists. This broad promotional strategy has helped in increasing awareness and adoption among both new and repeat prescribers[2][4].
Competitive Landscape
In the triptan market, sumatriptan, including branded and generic forms, holds the largest market share. In the 12 months ended December 2013, sumatriptan sales in the U.S. were approximately $2.8 billion, with injectable forms accounting for $381 million. Sumavel DosePro, being the only commercially available needle-free delivery system, differentiates itself from other injectable sumatriptan products that use needle-based injections[4].
Sales Projections
While specific sales forecasts for Sumavel DosePro beyond 2023 are not detailed in the latest sources, the overall trend in the migraine treatment market suggests continued growth. Given the unique advantages of Sumavel DosePro, it is likely to maintain a significant market share within the triptan segment.
Global Expansion
In addition to its presence in the U.S., Sumavel DosePro has been approved in several European countries, including Denmark, Germany, Sweden, Norway, and the United Kingdom. This global expansion is expected to further enhance its commercial potential[2][4].
Future Outlook
The future outlook for Sumavel DosePro is positive, driven by its unique delivery system, rapid onset of action, and the growing demand for effective migraine treatments. As the market continues to evolve with new therapies like CGRP inhibitors, Sumavel DosePro is likely to remain a valuable option for patients and healthcare providers due to its convenience and efficacy[3][4].
Key Takeaways
- Innovative Delivery System: Sumavel DosePro uses a needle-free delivery system, making it easier for patients to self-administer.
- Rapid Onset of Action: The drug can provide relief in as little as ten minutes.
- Market Growth: The migraine treatment market is expected to reach $6.3 billion by 2032.
- Sales Performance: Sumavel DosePro has shown promising sales figures since its launch in 2010.
- Broad Promotional Strategy: The drug is promoted to a wide range of healthcare providers.
- Global Expansion: Approved in several European countries, enhancing its global commercial potential.
FAQs
Q: What is Sumavel DosePro used for? A: Sumavel DosePro is used for the acute treatment of migraines with or without aura and cluster headaches in adults[1].
Q: How does Sumavel DosePro work? A: Sumavel DosePro uses compressed nitrogen gas to deliver sumatriptan succinate subcutaneously without a needle[5].
Q: What are the available doses of Sumavel DosePro? A: Sumavel DosePro is available in 4 mg and 6 mg single-dose prefilled systems[1].
Q: What is the maximum dose of Sumavel DosePro in a 24-hour period? A: The maximum cumulative injected dose in 24 hours is 12 mg, with doses separated by at least 1 hour[1].
Q: Is Sumavel DosePro covered by health insurance? A: Yes, Sumavel DosePro has achieved broad coverage in the U.S., with a reimbursement claims approval rate of approximately 83% since its launch[4].
Sources
- Drugs.com: Sumavel Dosepro: Package Insert / Prescribing Information.
- AnnualReports.com: Zogenix, Inc. - Annual Reports.
- Biospace.com: Migraine Drugs Market Size to Reach USD 6.3 Billion by 2032.
- AnnualReports.com: Zogenix, Inc. - Annual Reports (2013).
- Businesswire.com: Research and Markets: Global Sumavel DosePro (Migraine) - Forecast and Market Analysis to 2023.
More… ↓
